Cas No.: | 182410-00-0 |
Synonyms: | Sulfobutylether-β-Cyclodextrin |
SMILES: | O[C@H]([C@@H](O)[C@@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3C(O)[C@@H](O)[C@H]4O[C@@H]3CO)O[C@@H]2CO)O[C@@H]1CO)O[C@@H]5CO)[C@@H]5O[C@@H](O[C@@H]6CO)[C@H](O)C(O)[C@@H]6O[C@@H](O[C@@H]7CO)[C@H](O)[C@@H](O)[C@@H]7O[C@H]8O[C@H |
Formula: | C50H84Na2O41S2 |
M.Wt: | 1451.287 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SBE-β-CD (Sulfobutylether-β-Cyclodextrin) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. SBE-β-CD is a unique reproducible mixture of polyanionic β-cyclodextrin derivatives in which a sodium sulfonate salt is tethered to the lipophilic cyclodextrin cavity by a butyl ether group, or sulfobutylether (SBE). The sulfobutyl ether (SBE) substituent is introduced at the 2, 3, and 6 positions in one or more of the glucopyranose units in the cyclodextrin structure. The introduction of SBE substituents onto the β-cyclodextrin can produce preparations with different overall average degrees of substitution due to the proportion of multiple species present with different degrees of substitution, theoretically from 1 to 21 sites for substitution. SBE-β-CD, with on average 7 such SBE substituents per β-cyclodextrin, introduced by way of a reproducible patent-protected process, was chosen as the cyclodextrin preparation with the most desirable safety profile and drug association properties. |